toggle visibility Search & Display Options

Select All    Deselect All
 |   | 

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/acutrialsocom/public_html/refbase-ocom/includes/ on line 5275
  Record Links
Author Ursini, T.; Tontodonati, M.; Manzoli, L.; Polilli, E.; Rebuzzi, C.; Congedo, G.; Di Profio, S.; Toro, P. M.; Consorte, A.; Placido, G.; Lagana, S.; D'Amario, C.; Granchelli, C.; Parruti, G.; Pippa, L. url  openurl
  Title Acupuncture for the treatment of severe acute pain in herpes zoster: results of a nested, open-label, randomized trial in the VZV Pain Study Type of Study RCT
  Year 2011 Publication (up) BMC complementary and alternative medicine Abbreviated Journal BMC Complement Altern Med  
  Volume 11 Issue 46 Pages 1-8  
  Keywords AcuTrials; Pain; RCT; Nervous System Diseases; Herpes Zoster; Acu Versus Usual Care; Acupuncture; TCM Acupuncture Style; Fixed Acupuncture Protocol; Restricted Modalities, Acupuncture Only; Usual Care Control, Pharmaceutical  
  Abstract BACKGROUND: Data on the potential efficacy of acupuncture (AC) in controlling intense or very intense pain in patients with Herpes Zoster (HZ) has not been so far adequately assessed in comparison with standard pharmacological treatment (ST) by a controlled trial design. METHODS: Within the VZV Pescara study, pain was assessed in HZ patients on a Visual Analogue Scale (VAS) and by the McGill Pain Questionnaire (MPQ) both at the beginning and at the end of treatment. Response rates, mean changes in pain intensity, differences in total pain burden with an area-under-the-curve (AUC) method over a 1-year follow-up and differences in the incidence of Post-Herpetic Neuralgia (PHN) were evaluated. RESULTS: One hundred and two patients were randomized to receive either AC (n = 52) or ST (n = 50) for 4 weeks. Groups were comparable regarding age, sex, pain intensity at presentation and missed antiviral prescription. Both interventions were largely effective. No significant differences were observed in response rates (81.6% vs 89.2%, p = 0.8), mean reduction of VAS (4.1 +/- 2.3 vs 4.9 +/- 1.9, p = 0.12) and MPQ scores (1.3 +/- 0.9 vs 1.3 +/- 0.9, p = 0.9), incidence of PHN after 3 months (48.4% vs 46.8%, p = 0.5), and mean AUC during follow-up (199 +/- 136 vs 173 +/- 141, p = 0.4). No serious treatment-related adverse event was observed in both groups. CONCLUSIONS: This controlled and randomized trial provides the first evidence of a potential role of AC for the treatment of acute herpetic pain. TRIAL REGISTRATION: ChiCTR-TRC-10001146.  
  Address Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy.; CN – VZV Pain Study Group  
  Language Number of Treatments 8  
  Treatment Follow-up 52 Weeks Frequency >1/WK Number of Participants 102  
  Time in Treatment 4 Weeks Condition Pain
  Disease Category Pain OCSI Score  
  Notes Approved no  
  Call Number Serial 1190  
Permanent link to this record
Select All    Deselect All
 |   | 

Save Citations:
Export Records: